Grahame R, Clark B, Watson M, Polkey C
Department of Orthopedic Surgery, United Medical School, Guy's Hospital London, England.
Spine (Phila Pa 1976). 1991 Feb;16(2):172-5.
Twenty-six patients (13 men and 13 women), ranging in age from 38 to 75 years, with surgical and/or radiculographic evidence of chronic adhesive spinal arachnoiditis (CASA) were admitted to a randomly allocated, double-blind, 6-month crossover trial of d-penicillamine (500 mg/day) versus matching placebo. Assessments using subjective and objective criteria at 3-month intervals demonstrated no statistically significant effect with either d-penicillamine or placebo or between them. Thirteen of the 17 patients completing the trial expressed no clear preference. One patient preferred placebo. The remaining three patients who expressed strong preference for d-penicillamine (supported by objective data) subsequently maintained improvement on long-term therapy for up to 5 years. It is concluded that there may be a small subgroup of patients with CASA who might benefit from d-penicillamine therapy.
26例患者（13名男性和13名女性），年龄在38至75岁之间，有手术和/或影像学证据显示患有慢性粘连性脊髓蛛网膜炎（CASA），被纳入一项随机分配、双盲、为期6个月的交叉试验，比较青霉胺（500毫克/天）与匹配的安慰剂。每隔3个月使用主观和客观标准进行评估，结果显示青霉胺或安慰剂单独使用或两者之间均无统计学上的显著效果。完成试验的17例患者中有13例未表现出明确偏好。1例患者偏好安慰剂。其余3例强烈偏好青霉胺的患者（有客观数据支持）随后在长达5年的长期治疗中保持病情改善。结论是，可能有一小部分CASA患者可能从青霉胺治疗中获益。
